{"name":"Envisia Therapeutics","slug":"envisia-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOTlQzRkpQQlZDZXVlTFU3RzJWVV9HN3RhdWxyQ1gxdGJDaHFvZWpFQy1tOWRDbXhESDk2RkVWajdQZ2NhSTFncGlxTF9WTEVXMTdYZlhWdmd6NVI3b1FTbGdCZjNGTXBrVWp3S19GUF9DZlh0OFF3RXI0cU1XMFZhVXFzZjJZVkNpUU95bm9Jc0Y3Sm9yMkFoQ1dTTzNPb29PY0MwZ2VWaXJNR3d0WHgtY1BXV0FFWlMzZFRwdGl6VmR5U2xGMUNSLTRLdm9UQ2p6dVlvYU1BemYySTVLTE5va3ZFdmxvb0thRXNUNzlCVWJld0VuUDZn?oc=5","date":"2025-09-09","type":"pipeline","source":"PR Newswire","summary":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight - PR Newswire","headline":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQMHhfSGI1a3NjMkNsRC1ZdkRNUzJnS0FnMkhZbFBiRWF2Ykp0cHlVQ3IyZVRsZWNQQjNEaW5ESUd5V0ktU3NYYnI4NHAxT0tDLVFQZ0dDMlhyekNqZzI4RnRhX3FXV3VnX1VFODIwMkRvdUwxMEJqRlBjNnkwRktlODhwSEJOWEVVaERzXzlPTGdpSDNITmpFWXdjYldwUHkwWXVldjZXSkp6N3lZWC1LOEtqOGJRY05NdU52V1JFejhKX1BFS3NXRG1wd0NnckxyNmdIRWxoUGVnalJOeWp3Rl9TaDNHYThTOHc?oc=5","date":"2025-03-25","type":"pipeline","source":"PR Newswire","summary":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight - PR Newswire","headline":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxONzJwRzBpN1dGQ1h1QkRLdEFDQnRrcTJhMUkwSTJRdk9uZWJkVUZOd2VNel8tTWlJYzZkSzdJSG9nRXRuZFpkVFpEV1RKMDBvTWlkNnRaN3BzVUU5SWdZZDVwc1djWWhEaVhPRjlxWS15RDRJbm9hS29hQllqQktObGtUTDZ6OHlRQ2F4ZGlNQzFRUlpNakd2MkdiU244N3hLX3lka3FHS3VoTlVtbzJ2LXk2UHJ0ckZ5VjdGUi1MSUFRaU5YX2kxb2tOUnJoUFItM256NTFaaHhRSlpFRjdNVWE1eEZmY3RzdW5LZmZGcmI4dEVaNFlWcmZFQ3RXRVhfaGctMVhYTm9pdVMyaUx4ZC1feDh1SGk2czRLRUJzaDQydWVlWUdQUFR6bzJ5c09PaUtCWFNoQQ?oc=5","date":"2025-02-26","type":"pipeline","source":"GlobeNewswire","summary":"DURYSTA’s Market Potential Across the 7MM is Set to Soar - GlobeNewswire","headline":"DURYSTA’s Market Potential Across the 7MM is Set to Soar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPNFBrZ0ZESmtoTERKR3JLVTJYNWtoNFJGQk81amZvbHNnYjZIS0x1LURfeERoSmdGNG9zOXplNm4wN1ZWb3ZOWUQ0WjMySXZ3aXl2MkF6SmdZbE0xaVVYZFpiZ2VON3Y4aDlkaW83c0pJU3duZFluQzJBVzZEc2FYUXh6b1RxX3BfTERNMkcwS0h0aG8?oc=5","date":"2025-02-07","type":"pipeline","source":"EyeWorld","summary":"Next stop for glaucoma medications: sustained drug delivery - EyeWorld","headline":"Next stop for glaucoma medications: sustained drug delivery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOMmtscE5SNzV6aktJZFc1YnlvMXVPbEJSdk9nZUlQV1piN0NEQjQtcUlYMGs4eVVfLVdnZUJMZ0J5bElmbzZVVEo1dVlEb2pMMjZBdVdLSFk0djNyOTFTejZ0bUdyamtWZmZrWFo0Mm1HQk1nR0dJWnc2TUxVWEdHUkRVejNscnhWS2FVdUhlN1psYWhlcVoxd09nYkljd1BWMWxKNENBaW4zd25HSFNlQWxVeFZBOG50eHdLMlVmVngzNFJCc2d5M0J2ZVR2QVYxVXBPWUJLTWpKZG15TUdwMkxfUjVGU2YtNC1UYUw4VV9zM2dycDNNenJrRHpUUmtmTm8zVUJRX3JsMUtYT25QWnRHZXNGQjFRbGlTNGViLWZ0LWItUDFrbXhNcw?oc=5","date":"2016-10-17","type":"trial","source":"PR Newswire","summary":"Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After A Single Dose In Patients With Glaucoma - PR Newswire","headline":"Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After A Single D","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2016-01-12","type":"pipeline","source":"Newswise","summary":"Glaucoma Research Foundation to Host Fifth Annual Glaucoma 360 New Horizons Forum | Newswise - Newswise","headline":"Glaucoma Research Foundation to Host Fifth Annual Glaucoma 360 New Horizons Forum | Newswise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxOWmxLQzVUMTRaend4SE1IQzhWMlhUYTU2ZVJqV0g1UTdHOF90cU9DYXNtUDFoRnQxRHhFODZjN2RHbFprV0JPSC04a1B3WmY1V20wd0VvZzJ6Uk96MDVtZFJwdzNyWFpTXzFQczFNaGEtSkxDaGdMNndoN3VVWmcwMFNhR3pQb0lReGFRdjFvX29LUGhRcmNXdFBLZGNpYzVVelYyX055bUZ1WEFVekxiQ1pSWFNpeVpvNmdWY3l1MXpuWEwyWUZYZkM0MlFfbWljZi1sVU96NU5yckN4VHRObXM4cm1fbHpvUThFbjN3enFKS3dkZnlJX1NoSXdSbnhTbGZPNXh5X2xkckViMHEzMUZoSUkwZFZrR1Y0?oc=5","date":"2015-10-06","type":"trial","source":"PR Newswire","summary":"Envisia Therapeutics' Lead Product Candidate, ENV515 (travoprost XR), Achieves Primary Efficacy Endpoint In Phase 2a Glaucoma Clinical Trial - PR Newswire","headline":"Envisia Therapeutics' Lead Product Candidate, ENV515 (travoprost XR), Achieves Primary Efficacy Endpoint In Phase 2a Gla","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1uN2R3LUxyenhPQjZqc0RvTmZEaVNwNmQ3dzB2UHBzVmx1NEs0RjRUcHhXcWxHZk9VcnN0NHF2MWlLRFFZY3BFTXVWa244VUNzZjZXakJubW9CU2stSHFWTVZMcTlhYTZJZ1hqUXplZG9EQQ?oc=5","date":"2014-11-28","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"30 Top VC Firms for Biotechs - Genetic Engineering and Biotechnology News","headline":"30 Top VC Firms for Biotechs","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}